Ozarelix Phase 2 Data in Benign
Selected Abstract
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association.
* Ozarelix Effective in Improving Symptoms and Urine Flow, With Long Lasting Effect in Phase 2 Study * Phase 3 Registrational Trial Expected to Begin in 2nd Half 2007 IRVINE, Calif., May 23 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced Phase 2 safety and efficacy data ... May 23, 2007; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association.
2.
/C O R R E C T I O N -- Spectrum Pharmaceuticals, Inc./.
|
